“While we have been present in India for years and achieved sales of our advanced VeriQ™ and MiraQ™ product lines, we believe a solution tailored to local needs will accelerate adoption both in the private and public healthcare segment."
Medistim launches the SonoQ™ at the ICC congress in New Delhi, India 11-13 November 2016
“Medistim is the market leader with high-end products for surgical guidance and blood flow measurement in cardiac-, vascular and transplant surgery worldwide and in India with marquee names such as AIIMS, B.L Kapoor, Hinduja hospital, Lilavati hospital and Medica Superspeciality hospital among some of the key users of our technology. However, we have been lacking a TTFM system tailored to reach a broader segment in emerging markets like India,” says Medistim President and CEO, Kari E. Krogstad. “While we have been present in India for years and achieved sales of our advanced VeriQ™ and MiraQ™ product lines, we believe a solution tailored to local needs will accelerate adoption both in the private and public healthcare segment. We look forward to continue our collaboration with Indian surgeons and support their work to achieve the best possible surgical outcomes.”
The SonoQ is a device that measures blood flow accurately using TTFM technology, which is the de facto standard worldwide. The features of SonoQ have been tailored to address the specific needs of emerging markets such as India, which is a key focus area for Medistim. The system has a small footprint, and can easily be shared between departments and operating rooms, supporting high productivity in the hospital.
The SonoQ is used intraoperatively for quality assessment of cardiac, vascular and organ transplant procedures wherein TTFM has been found to directly effect patient outcomes in numerous independent medical studies done worldwide.
One of the most important target markets for the SonoQ is India, a market with about 150,000 coronary artery bypass procedures per year, which is very low compared to the population size of 1.3 billion, and therefore expected to grow. In collaboration with our local partner, Medistim is launching the new product at the International Coronary Congress in New Delhi, India, on November 11-13. This meeting is dedicated to state of the art surgical coronary revascularization, and the program highlights the necessity of surgical guidance and quality assessment based on intraoperative ultrasound and TTFM.